2026-10-11T21:30:14Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33952378 2026-09-21T12:00:22Z category_388 portal_316 item_type_3 month_year_09_2026

Table 2_Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event.pdf Kristin Mersmann (25083274) Martin Metzenmacher (10744329) Gregor Zaun (9266564) Marcel Wiesweg (11438317) Filiz Oezkan (25083277) Jane Winantea (9085471) Christian Taube (35629) Dirk Theegarten (44347) Martin Schuler (162011) Lale Umutlu (505989) Servet Bölükbas (20857235) Fabian Doerr (22287037) Daniel Messiha (11221123) Marcel Opitz (14589725) Wilfried EE Eberhardt (25083280) Johannes Wienker (9085462) Oncology and Carcinogenesis not elsewhere classified chemotherapy induction therapy lung cancer pulmonary embolism thromboembolic complications Introduction<p>Pulmonary embolism (PE) at initial diagnosis and during first-line systemic treatment is clinically relevant in patients with lung cancer. However, real-world incidence of subclinical PE is not well established.</p>Methods<p>Retrospective single-center analysis of patients at least 18 years old with non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) who received first-line/induction systemic therapy. All patients underwent contrast-enhanced computed tomography (CT) of the thorax with bolus tracking for PE detection. Treatment response was assessed by restaging at weeks 6 and 12 after treatment initiation.</p>Results<p>A total of 373 patients treated between 2019 and 2022 were included (261 NSCLC, 112 SCLC; 179 women and 194 men; median age 66 years [range, 22 to 86]; median smoking history 40 Pack Years [range, 0-150]). There was a predominance of locally advanced and metastatic disease (IB-IIB, n = 22; IIIA-C, n = 123; IVA-B, n = 228). Adenocarcinoma was the predominant histology among NSCLC cases (LUAD, n = 146), followed by squamous cell carcinoma and other NSCLC subtypes combined (n = 115); 112 patients had SCLC.</p><p>PE was detected in 61/373 patients, of whom 58 (95%) had subclinical PE. In NSCLC, body-mass-index (BMI) was independently associated with occurrence of PE (OR = 1.111, p = 0.005), while central tumor localization (OR 5.637, p = 0.028) and vascular infiltration (OR 7.683, p = 0.010) were significantly associated with PE in SCLC. All patients with PE received anticoagulants according to national and international guidelines and no PE-related deaths occurred.</p>Conclusion<p>This single-center analysis demonstrates a high incidence of subclinical PE in newly diagnosed lung cancer patients and identifies clinical risk factors associated with PE development.</p> 2026-09-21T12:00:22Z Dataset Dataset 10.3389/fonc.2026.1886848.s002 https://figshare.com/articles/dataset/Table_2_Subclinical_pulmonary_embolism_in_first-line_induction_therapy_of_lung_cancer_-_a_remaining_clinically_relevant_adverse_event_pdf/33952378 CC BY 4.0